louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06342856: Evaluation of Treatment With Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile Men With Idiopathic Oligoasthenoteratospermia
Official title: Evaluation of Treatment With Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile Men With Idiopathic Oligoasthenoteratospermia a Placebo Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Infertility Unexplained
Oligospermia
Keywords: infertility
oligospermia
coenzyme Q1o
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-04-02
Enrollment: 120
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Evaluation of treatment with Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile men with Idiopathic Oligoasthenoteratospermia

Detailed description: Evaluation of treatment with Coenzyme Q10 and L-Carnitine on Semen Parameters in Infertile men with Idiopathic Oligoasthenoteratospermia a placebo controlled clinical trial

Eligibility criteria: Inclusion Criteria:

* of in¬fertility of 1 year or more without the use of contraception

Exclusion Criteria:

* o Active genital infections.

  * Patients with ejaculatory dysfunction
  * Azoospermia

Primary outcomes:
measure: Changes in Semen analysis parameters compared to baseline
timeFrame: 6 months
Secondary outcomes:
measure: Serum hormone levels ([FSH], [LH], testosterone, and prolactin) levels compared to baseline and Cost analysis
timeFrame: 6 moths
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
References:
citation: Salvio G, Cutini M, Ciarloni A, Giovannini L, Perrone M, Balercia G. Coenzyme Q10 and Male Infertility: A Systematic Review. Antioxidants (Basel). 2021 May 30;10(6):874. doi: 10.3390/antiox10060874.
Clinical trial NCT01066156: Post-Traumatic Stress Disorder (PTSD) and Seroquel
Official title: Functional Reciprocity Between Heightened Stress Reactivity and Emotional Numbing in PTSD: Novel Predictors of Pharmacotherapeutic Outcomes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Post-Traumatic Stress Disorder
Keywords: Post-traumatic Stress Disorder
PTSD
Seroquel
fMRI
Lead sponsor: Cambridge Health Alliance
Sponsor class: OTHER
First posted: 2010-02-10
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.

Detailed description: An initial telephone interview will be conducted to determine if potential subjects meet the basic study requirements. If no obvious counterindications are present, subjects will be scheduled for a screening visit. After briefing the subjects on the reasons for the research, they will be given an opportunity to read the Informed Consent Form, approved by the Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to signing it. Subjects will be given a copy of the signed Consent Form. Each subject will complete a standardized interview schedule designed to obtain personal and background data along with psychodiagnostic and psychometric evaluations. An open-label treatment will be utilized for all patients. Seroquel tablets will be flexibly dosed and begun at a target dose of 25 mg per day and taken over an 8 week period.

Eligibility criteria: Inclusion Criteria:

* Provision of written informed consent
* Fluency in English
* A diagnosis of PTSD
* No pregnancy
* Right-handedness

Exclusion Criteria:

* Pregnancy or lactation
* Any cognitive impairment that precludes informed consent
* Known intolerance or lack of response to Seroquel
* Previous enrollment or randomization of treatment in the present study
* Participation in another drug trial within 4 weeks prior enrollment into this study
* Patients with Diabetes Mellitus
* History of allergic reaction or hypersensitivity to Seroquel
* Contraindications to magnetic resonance imaging
* Treatment with an effective medication for PTSD

Primary outcomes:
measure: Change From Baseline in PTSD Symptomatology at the Week 8 Timepoint.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Somerville
country: United States
facility: Central Street Health Center
state: Massachusetts
Study officials:
affiliation: CHA
name: Igor Elman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00611156: Examination of the Effects of Four Different Spices on Energy Metabolism
Official title: Bioactive Food Ingredients and Energy Metabolism: The Effects of Ginger, Black Pepper, Horseradish and Mustard on Meal-Induced Thermogenesis and Fat Oxidation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Thermogenesis
Meal-induced thermogenesis
energy expenditure
fat oxidation
bioactive ingredients
spices
ginger
horseradish
black pepper
mustard
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: University of Aarhus
First posted: 2008-02-08
Enrollment: 22
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The objective of this study is to examine whether four different spices (ginger, black pepper, horseradish and mustard) are able to increase energy metabolism.

Since chili and other spices have been shown to increase energy expenditure compared to placebo, we expect that some or all of the four spices may actually increase energy expenditure - although not to a large degree.

Detailed description: Several pungent food ingredients, such as chili,and also other bioactive food ingredients, e.g. green tea, have been shown to be able to increase energy expenditure and fat oxidation during the hours following a meal containing the bioactive ingredient. Furthermore, we will also look at the subjects own feelings of appetite and thereby examine whether the appetite is affected by the spicy food. We expect to see some small effects on these parameters.

Eligibility criteria: Inclusion Criteria:

* male
* healthy and not use medication (regularly)
* normal weight
* non smoker
* tolerate and like spicy food
* stable body weight last two months

Exclusion Criteria:

* increased blood pressure
* abnormal EKG
* mental, metabolic and chronic diseases

Primary outcomes:
measure: energy expenditure
timeFrame: November 2007
Secondary outcomes:
measure: blood pressure
timeFrame: December 2007
measure: heart rate
timeFrame: December 2007
measure: VAS-scores for appetite, hunger, fullness, etc. - and palatability
timeFrame: November 2007
measure: tolerance
timeFrame: November 2007
measure: Fat and carbohydrate oxidation
timeFrame: November 2007
measure: Meal-induced thermogenesis
timeFrame: November 2007
Other outcomes:
Locations:
city: Frederiksberg
country: Denmark
facility: Department of Human Nutrition, The Royal Veterinary and Agricultural University
Study officials:
affiliation: Department of Human Nutrition, RVAU
name: Arne Astrup, Professor MD
role: STUDY_CHAIR
References:
citation: Gregersen NT, Belza A, Jensen MG, Ritz C, Bitz C, Hels O, Frandsen E, Mela DJ, Astrup A. Acute effects of mustard, horseradish, black pepper and ginger on energy expenditure, appetite, ad libitum energy intake and energy balance in human subjects. Br J Nutr. 2013 Feb 14;109(3):556-63. doi: 10.1017/S0007114512001201. Epub 2012 Jul 5.
Clinical trial NCT00509756: Study Evaluating FXR-450 in Healthy Japanese Men
Official title: Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of FXR-450 Administered Orally to Healthy Japanese Male Subjects
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Healthy
Keywords: healthy subjects
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2007-07-31
Enrollment: 56
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of a single dose of FXR-450 in healthy Japanese men.

Detailed description: This study was terminated on May 2008. The reason for termination was due to pharmacokinetics issues. The decision to terminate was not due to safety and tolerability.

Eligibility criteria: Inclusion Criteria:

* Men aged 20 to 45 years.
* Healthy as determined by the investigator.
* Nonsmoker or smoker of fewer than 10 cigarettes per day.

Exclusion Criteria:

* A history or active presence of clinically important medical disease.
* Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article (e.g., resection of liver, kidney, gallbladder, or gastrointestinal tract).

Primary outcomes:
measure: The primary outcome is safety and tolerability.
timeFrame: 4 days
Secondary outcomes:
measure: Pharmacokinetics
timeFrame: 4 days
Other outcomes:
Locations:
city: Tokyo
country: Japan
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
Clinical trial NCT02615756: Molecular and Functional Neurobiology of Physical Exercise
Official title: Molecular and Functional Neurobiology of Physical Exercise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Exercise Behavior (Liking/Aversion)
Lead sponsor: Turku University Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Academy of Finland
name: Novo Nordisk A/S
name: Juho Vainio Foundation
name: University of Turku
First posted: 2015-11-26
Enrollment: 24
Sex: MALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: In this study, we use positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) to study brain mechanisms that contribute to physical exercise-induced reward. We examine whether acute physical exercise releases endogenous opioids in the brain, and whether it modulates brain responses to viewing appetizing foods. Unraveling these mechanism are instrumental from a public health perspective, given the undisputed positive health effects of physical exercise.


Eligibility criteria: Inclusion Criteria:

1. Native Finnish speaker
2. Age \> 18 years
3. Western Caucasian origin

Exclusion Criteria:

1. Age \< 18 or \> 65
2. History or current mental disorder
3. BMI \> 27 kg/m2
4. Use of drugs that influence the central nervous system, including nicotine
5. Poor compliance
6. Any chronic medical defect or injury which hinder or interfere everyday life
7. Eating disorder
8. Current or past excessive use of alcohol or substance abuse
9. Past dose of radiation from medical research such that the annual effective dose will exceed 10 mSv
10. Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results
11. Presence of any ferromagnetic objects that would make MR imaging contraindicated

Primary outcomes:
measure: Binding of [11C]carfentanil in brain confirmed by positron emission tomography
timeFrame: Baseline and 20 min after physical exercise completion
Secondary outcomes:
Other outcomes:
Locations:
city: Turku
country: Finland
facility: Turku PET Centre
Study officials:
References:
Clinical trial NCT04021056: Observational Study on Patients With Hepatocellular Carcinoma (HCC)
Official title: Observational Study on Patients With Hepatocellular Carcinoma (HCC)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatocellular Carcinoma
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2019-07-16
Enrollment: 3000
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed and treated as HCC in Liver Cancer Center, Nanfang Hospital

Brief summary: This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of HCC;
* Age ≥ 16 years;
* Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
* Good compliance with clinical treatment.

Exclusion Criteria:

* Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
* Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
* HCC diagnosed after liver transplantation;
* Poor compliance or important data deficient.

Primary outcomes:
measure: Evaluate the overall survival rate of all HCC patients
timeFrame: 10 years
measure: Evaluate the recurrence free survival rate of HCC patients after curative treatments
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Nanfang Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT01587456: Arteos II Study: Relationship Between Osteoporosis and Arterial Rigidity Within Fractured Patients Cohort
Official title: Relationship Between Osteoporosis and Arterial Rigidity Within Fractured Patients Cohort.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Osteoporosis
Keywords: Osteoporosis
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2012-04-30
Enrollment: 300
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women and men \> 60 years of age with medical history of low energy fracture andradiologic osteoporosis with DXA Tscore at -2,5 DS.

Brief summary: The investigators planned to study relationship between osteoporosis and arterial rigidity within fractured patients cohort.


Eligibility criteria: Inclusion Criteria:

* women and men \> 60 years of age
* medical history of low energy fracture
* DXA Tscore -2,5 DS
* FREE AND INFORMED CONSENT SIGNED

Exclusion Criteria:

* women and men \< 60 years of age
* Corticoids treatment
* Breast cancer or prostat cancer medical history
* High energy fracture (traumatic fracture)
* No social security affiliation
* Incapacity to informed consent signed.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Vandoeuvre
country: France
facility: CHU de Brabois Endocrinology
Study officials:
affiliation: CHU de Brabois Endocrinology
name: Georges WERYHA, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02327156: Dexmedetomidine as an Adjuvant for Sub-Tenon's Anesthesia
Official title: The Effect of a Low-dose Dexmedetomidine as an Adjuvant to Levobupivacaine in Patients Undergoing Vitreoretinal Surgery Under Sub-Tenon's Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vitreoretinal Surgery Under Sub-Tenon's Anesthesia
Keywords: Dexmedetomidine
Lead sponsor: Magrabi Eye & Ear Hospital
Sponsor class: OTHER
First posted: 2014-12-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The investigator evaluated the motor and sensory block durations and the postoperative analgesic effects of adding dexmedetomidine to levobupivacaine for sub-Tenon's anesthesia in patients undergoing vitreoretinal surgery. Motor and sensory block durations were considered as a primary endpoint.

Detailed description: Background: The investigator evaluated the motor and sensory block durations and the postoperative analgesic effects of adding dexmedetomidine to levobupivacaine for sub-Tenon's anesthesia in patients undergoing vitreoretinal surgery. Motor and sensory block durations were considered as a primary endpoint.

Methods: The investigator investigated 60 patients subjected to vitreoretinal surgery under sub-Tenon's anesthesia. The patients were randomly divided equally into 1 of 2 groups conferring to the local anesthesia (LA) solution used to receive either 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline (group L) or 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline (group LD). The total volume of the LA solution used was 5 mL. Motor block (akinesia) and sensory block durations were evaluated until the return of normal motor and sensory function. The sedation level was assessed during the surgery period and 24 hours postoperatively together with the degree of postoperative pain and the efficiency of postoperative analgesia. The sleep quality of the first postoperative night was assessed using the Consensus Sleep Diary (CSD).

Eligibility criteria: inclusion criteria:

* satisfactory akinesia
* predictable surgical time to be less than 3 hours were inclusion criteria for this study

Exclusion Criteria:

* incorporated patients younger than 18 years,
* patients with a single eye,
* history of sleep apnea,
* severe cardiac disease, and
* drug abuse or
* if there was any contraindication to LA.

Primary outcomes:
measure: the motor and sensory block durations
timeFrame: participants will be followed for the duration of hospital stay, an expected average of 24 hours
Secondary outcomes:
measure: sleep quality of the 1st postoperative night
timeFrame: 24 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06905756: Comparative Effect of Accelerated Rehabilitation and Eccentric Strengthening Exercises on Patients With AT
Official title: Compartive Effect of Accelerated Rehabilitation and Eccentric Strengthing Exercises on Patient With Achilles Tendinopathy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Achilles Tendinopathy
Lead sponsor: Superior University
Sponsor class: OTHER
First posted: 2025-04-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: A common overuse injury to the Achilles tendon, Achilles tendinopathy frequently causes pain, restricted range of motion, and functional impairment.

Detailed description: The purpose of this randomized clinical research is to evaluate the benefits of eccentric strengthening exercises and rapid rehabilitation on Achilles tendinopathy patients. Using techniques including TENS, isometric exercises, balance training, and endurance exercises, the 12-week accelerated rehabilitation program emphasizes pain management, mobility restoration, and functional recovery through incremental phases. However, in order to improve tendon strength and resilience, eccentric strengthening entails progressively raising resistance and functional loading. Both approaches are backed by earlier research but lack direct comparison in terms of effectiveness. This study will open the door for more research and improve rehabilitation techniques worldwide by adding to the expanding corpus of material on Achilles tendinopathy care.

Eligibility criteria: Inclusion Criteria:

* Male and female patients, age greater than 18 years, clinically diagnosed with Achilles tendinopathy.
* Participants that are clinically diagnosed with Achilles tendinopathy.
* Duration of symptoms or pain for more than 1 month.
* Positive clinical tests, such as Thompson test, confirming Achilles tendinopathy.
* Tenderness to palpation along the Achilles tendon or localized pain during activity.
* Patients with a history of overuse injuries related to repetitive activities, such as running or jumping.

Exclusion Criteria:

* Following participants will be excluded from this study:
* Presence of systemic conditions such as rheumatoid arthritis, diabetes, or other inflammatory or neuromuscular disorders.
* History of complete Achilles tendon rupture or previous surgical intervention on the affected tendon.
* Patients with other lower limb injuries or conditions (e.g., fractures, ligament tears) that could interfere with Achilles tendinopathy treatment.
* Severe tendon degeneration or calcification confirmed by imaging, unsuitable for rehabilitation.

Primary outcomes:
measure: Numerical pain rating scale
timeFrame: 12 Months
measure: WHOQOL (world health organization and quality of life)
timeFrame: 12 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Punjab Social Security Health Management Hospital Manga Raiwind
state: Punjab
Study officials:
References:
Clinical trial NCT01128556: The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing
Official title: The Evaluation of the Effect of Bepreve, a Topical Ocular Antihistamine, on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Histamine Responsive Allergy Patients
Keywords: allergic conjunctivitis
histamine skin testing
Lead sponsor: North Texas Institute for Clinical Trials
Sponsor class: OTHER
First posted: 2010-05-24
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER

Brief summary: To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.


Eligibility criteria: Inclusion Criteria:

* Healthy male and female subjects, 18 to 65 years of age
* Patients must demonstrate a positive reaction to a Histamine skin-prick test. Manifested by a histamine-induced wheal of \>3mm in diameter over the normal saline control after 15 minutes of elapsed time

Exclusion Criteria:

* Significant signs and symptoms of currently active allergic disease (SAR, perennial allergic rhinitis, episodic allergic rhinitis)
* Upper respiratory tract infection, sinusitis, asthma or flu-like symptoms within 2 weeks prior to visit 1
* Subjects who have dermatographism or other skin conditions which might interfere with the interpretation of the skin test results
* Subjects who are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy
* Known hypersensitivity to the investigational product or to drugs with similar chemical properties
* Pregnancy and/or breast feeding
* Use of antihistamines, NSAIDS, steroids, or other drugs which may affect the skin-response
* Use of any medications or agents that are not specified above that may confound the interpretation of the results

Primary outcomes:
measure: measurement of Wheal and Flare response from histamine skin-prick testing
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Worth
country: United States
facility: North Texas Institute for Clinical Trials
state: Texas
Study officials:
affiliation: North Texas Institute for Clinical Trials
name: Bob Q Lanier, MD
role: PRINCIPAL_INVESTIGATOR
References: